Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,265 across all filing types
Latest filing 2021-07-16 Annual Report
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 34(1) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find enclosed the Annual Report of the Company for the financial year ....
Annual Report Classification · 100% confidence The document is a letter addressed to stock exchanges (NSE and BSE) dated July 16, 2021, enclosing the Annual Report for the financial year ended March 31, 2021. It references compliance with SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, specifically Regulation 34(1), which mandates submission of annual reports. The letter states that the Annual Report is enclosed and also available on the company's website. The document includes detailed content typical of an Annual Report such as Managing Director's statement, corporate overview, statutory reports, financial statements including auditor's report, balance sheet, profit and loss statement, and notes to financial statements. The length of the document (15,000 characters) and the presence of substantive financial data and management discussion confirm it is the full Annual Report, not just an announcement or a notice. Therefore, the document fits the definition of an Annual Report (10-K). FY 2021
2021-07-16 English
Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the Notice of the 42nd Annual General ....
AGM Information Classification · 100% confidence The document is a detailed notice of the 42nd Annual General Meeting (AGM) of AstraZeneca Pharma India Limited, including the agenda items such as adoption of financial statements, appointment of directors, appointment of auditors, and other resolutions. It references the Annual Report for the financial year ended March 31, 2021, but the document itself is the Notice of the AGM, not the Annual Report. The document is lengthy (15,000 characters) and contains the full notice text, meeting details, and voting instructions, which aligns with materials shared during an AGM. Therefore, this document fits the category of AGM Information (AGM-R).
2021-07-16 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the loss of share certificates. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provides details of the lost share certificates and shareholders. There is no financial data, report, or presentation content. The document is an official notification related to share certificates, which fits best under Regulatory Filings (RNS) as it is a regulatory announcement that does not fit other specific categories.
2021-07-09 English
Pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015, the Company is intimating the request received relating to Loss of share certificate and issue of duplicate share certificate ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the loss of share certificates. It references compliance with SEBI Listing Obligations and Disclosure Requirements but does not contain financial data, management discussion, or report content. It is an announcement related to share certificates, which fits the category of Regulatory Filings (RNS) as it is a compliance notification rather than a financial report or other specific filing type.
2021-07-09 English
In terms of SEBI's Circular No. CIR/CFD/CMD1/27/2019 dated February 8, 2019, we furnish herewith the Secretarial Compliance Report, for the year ended March 31, 2021.
Regulatory Filings Classification · 95% confidence The document is titled 'Secretarial Compliance Report' for the year ended March 31, 2021, and is addressed to stock exchanges. It references compliance with SEBI regulations and lists various securities regulations examined. The document is a report by a practicing company secretary certifying compliance with regulatory provisions for the financial year. It does not contain financial statements or management discussion but focuses on regulatory compliance and secretarial matters. This type of document is a compliance report related to governance and regulatory adherence rather than a financial report or announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance reports that do not fit other specific categories.
2021-06-29 English
Copy of the intimation pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, pertaining to notice of demand from National Pharmaceutical ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) regarding a regulatory notice received from the National Pharmaceutical Pricing Authority (NPPA) about a pricing dispute and demand for payment. It discusses legal and regulatory compliance issues, the company's position, and a writ petition filed in response. There are no financial statements, earnings data, or detailed financial analysis present. The document is an announcement of a legal/regulatory matter affecting the company, not a financial report or earnings release. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about a legal demand and company response under SEBI listing obligations.
2021-06-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.